404 Not Foundnginx/1.6.1 Financial Sector Fund July 8 News GF Innovative Medical Two-Year Holding Period Hybrid Securities Investment Fund (Abbreviation: GF Innovative Medical Two-Year Holding Period Hybrid C, Code 010732) Net Value on July 07 It fell 2.11%, attracting investors'

2024/06/1018:36:32 finance 1321
404 Not Foundnginx/1.6.1 Financial Sector Fund July 8 News GF Innovative Medical Two-Year Holding Period Hybrid Securities Investment Fund (Abbreviation: GF Innovative Medical Two-Year Holding Period Hybrid C, Code 010732) Net Value on July 07 It fell 2.11%, attracting investors' - DayDayNews

404 Not Found

nginx/1.6.1

Financial Fund July 8 News GF Innovation Medical Two-Year Holding Period Hybrid Securities Investment Fund (Abbreviation: GF Innovation Medical Two-Year Holding Period Hybrid C, Code 010732) Net Value on July 7 It fell 2.11%, attracting investors' attention. The current net value of fund unit is 0.8089 yuan, and the cumulative net value is 0.8089 yuan.

Guangfa Innovation Medical's two-year holding period hybrid C fund has gained -19.11% since its establishment, -13.44% since this year, 13.24% in the past month, and -33.94% in the past year.

This fund has distributed 0 dividends since its establishment, with a cumulative dividend amount of 0 billion yuan. The fund is currently open for subscription. The fund manager of

is Wu Xingwu. He has managed the fund since March 19, 2021, with a return of -17.37% during his tenure. The latest fund regular report of

shows that the fund holds heavy positions in Asymchem ( holding proportion is 10.58%), Wuxi AppTec (position proportion 9.92%), Porton shares (position proportion 9.83%), Zhifei Biologics (position ratio 6.54%), WuXi Biologics (position ratio 4.56%), Tigermed (position ratio 4.03%), Pien Tze Huang (position ratio 3.51%), Pharmaron (position ratio 3.38%) ), Bethany (position ratio 3.06%), Aier Ophthalmology (position ratio 2.99%).

During the reporting period, Fund Investment Strategy and Operational Analysis

In the first quarter, the market trend was weak, the pharmaceutical sector experienced a large decline, and the net value of the Fund had a large retracement. The

market has adjusted to the current stage. The valuations of some high-quality companies have returned to relatively low positions in the past three years. Many companies whose long-term development logic is affected by policies are now relatively stable. We believe that the price/performance ratio of many assets is already at a relatively low level. appropriate level.

The ability of an enterprise is the most important factor for us, but policy disturbances and changes in economic climate are also important external factors that affect the development of the enterprise. We will consider it comprehensively and strive to find a balance point to create profits.

Fund performance during the reporting period

finance Category Latest News